NRSN on Nasdaq
NeuroSense Therapeutics Ltd.
Pharmaceutical preparations company based in Herzliya, listed on Nasdaq (NRSN). Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
-$11.1MNet income, fiscal 20252
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-$7.7MFree cash flow2
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development expenses | -$6.2M | -$5.7M | -$7.3M |
| General and administrative expenses | -$4.9M | -$4.2M | -$4.8M |
| Operating loss | -$11.1M | -$9.9M | -$12.0M |
| Financing income (expenses), net | -$40.0K | -$308.0K | $1.9M |
| Net loss and comprehensive loss | -$11.1M | -$10.2M | -$10.1M |
| Basic net loss per share (in Dollars per share) | -$0.44 | -$0.54 | -$0.74 |
| Diluted net loss per share (in Dollars per share) | -$0.44 | -$0.54 | -$0.74 |
| Weighted average number of ordinary shares used in computing basic net loss per share (in Shares) | 25.5M shares | 18.6M shares | 13.6M shares |
| Weighted average number of ordinary shares used in computing diluted net loss per share (in Shares) | 25.5M shares | 18.6M shares | 13.6M shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $166.0K | $3.4M | ||
| Other receivables | $565.0K | $989.0K | ||
| Restricted deposits | $47.0K | $35.0K | ||
| Total current assets | $778.0K | $4.4M | ||
| Property and equipment, net | $58.0K | $66.0K | ||
| Right of use assets | $170.0K | $84.0K | ||
| Restricted deposit | $22.0K | $23.0K | ||
| Total non-current assets | $250.0K | $173.0K | ||
| Total assets | $1.0M | $4.6M | ||
| Trade payables | $799.0K | $1.2M | ||
| Other current liabilities | $1.7M | $832.0K | ||
| Total current liabilities | $2.5M | $2.0M | ||
| Lease liability less current maturity | $72.0K | |||
| Total non-current liabilities | $72.0K | |||
| Total liabilities | $2.6M | $2.0M | ||
| Share Premium and Capital Reserve | $46.2M | $39.2M | ||
| Accumulated deficit | -$47.8M | -$36.7M | ||
| Total shareholders equity (deficit) | -$1.6M | $2.6M | -$1.8M | $5.8M |
| Total liabilities and shareholders equity | $1.0M | $4.6M | ||
| Ordinary shares, shares authorized (in Shares) | 90.0M shares | 90.0M shares | ||
| Ordinary shares, shares issued (in Shares) | 32.6M shares | 23.2M shares | ||
| Ordinary shares, shares outstanding (in Shares) | 32.6M shares | 23.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $166.0K | $3.4M | ||
| Other receivables | $565.0K | $989.0K | ||
| Restricted deposits | $47.0K | $35.0K | ||
| Total current assets | $778.0K | $4.4M | ||
| Property and equipment, net | $58.0K | $66.0K | ||
| Right of use assets | $170.0K | $84.0K | ||
| Restricted deposit | $22.0K | $23.0K | ||
| Total non-current assets | $250.0K | $173.0K | ||
| Total assets | $1.0M | $4.6M | ||
| Trade payables | $799.0K | $1.2M | ||
| Other current liabilities | $1.7M | $832.0K | ||
| Total current liabilities | $2.5M | $2.0M | ||
| Lease liability less current maturity | $72.0K | |||
| Total non-current liabilities | $72.0K | |||
| Total liabilities | $2.6M | $2.0M | ||
| Share Premium and Capital Reserve | $46.2M | $39.2M | ||
| Accumulated deficit | -$47.8M | -$36.7M | ||
| Total shareholders equity (deficit) | -$1.6M | $2.6M | -$1.8M | $5.8M |
| Total liabilities and shareholders equity | $1.0M | $4.6M | ||
| Ordinary shares, shares authorized (in Shares) | 90.0M shares | 90.0M shares | ||
| Ordinary shares, shares issued (in Shares) | 32.6M shares | 23.2M shares | ||
| Ordinary shares, shares outstanding (in Shares) | 32.6M shares | 23.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss for the year | -$11.1M | -$10.2M | -$10.1M |
| Depreciation | $16.0K | $22.0K | $21.0K |
| Share based compensation | $2.1M | $557.0K | $1.5M |
| Revaluation of liability with respect to warrants | -$46.0K | -$2.2M | |
| Financing expenses, net | -$46.0K | $323.0K | $473.0K |
| Decrease in operating right of use asset | $84.0K | $78.0K | $74.0K |
| Decrease in operating lease liability | -$73.0K | -$69.0K | -$69.0K |
| Decrease (increase) in other current assets | $424.0K | -$753.0K | $19.0K |
| Increase (decrease) in trade payables | -$361.0K | -$299.0K | $961.0K |
| Increase in other payables | $1.3M | $262.0K | $928.0K |
| Net cash used in operating activities | -$7.7M | -$10.1M | -$8.4M |
| Purchase of property and equipment | -$8.0K | -$3.0K | -$29.0K |
| Redemption of (investment in) short-term deposits | $3.5M | ||
| Redemption of (investment in) restricted deposit, net | $4.0K | -$3.0K | |
| Net cash provided by (used in) investing activities | -$8.0K | $1.0K | $3.5M |
| Exercise of warrants and options | $22.0K | $5.0K | |
| Issuance of shares, warrants and pre-funded warrants | $4.5M | $11.3M | $4.3M |
| Issuance costs | -$121.0K | -$391.0K | -$364.0K |
| Net cash provided by financing activities | $4.4M | $10.9M | $4.0M |
| Effects of exchange rate changes on cash and cash equivalents | $35.0K | -$41.0K | $8.0K |
| Increase (decrease) in cash and cash equivalents | -$3.2M | $738.0K | -$903.0K |
| Reclassification of warrants into equity | $1.4M | ||
| Bonus accrual reclassification to equity (See Note 13) | $1.4M | ||
| Conversion of liability into shares | $410.0K | ||
| Recognition of right of use assets | $170.0K | ||
| Interest received | $13.0K | $2.0K | $179.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led NeuroSense Therapeutics Ltd., and when. Pick a name to see everywhere that person has worked.
- Chief executive officerAlon Ben-Noon Mar 30, 2026 to now8
- Chief financial officerOr Eisenberg Apr 1, 2026 to now9
Board members and other officers (8)
- Chief Medical OfficerFerenc Tracik Mar 18, 2026 to now10
- General ManagerHagit Binder Mar 18, 2026 to now11
- Chief Technology OfficerNiva Russek-Blum Mar 30, 2026 to now12
- Board memberCary J. Claiborne Mar 18, 2026 to now13
- Board memberChristine A. Pellizzari Mar 18, 2026 to now14
- Board memberMark Leuchtenberger Mar 18, 2026 to now15
- Board memberRoy Golan Mar 18, 2026 to now16
- Board memberRevital Mandil-Levin Mar 31, 2026 to now17
Named in SEC Form D filings
People the company listed in its private-offering notices.
Timeline
- Mar 30, 2026New chief executive Alon Ben-Noon becomes CEO8
Filings
306 filings to the SEC since October 2021: 5 annual reports, 15 insider forms, 10 large holders, 3 private raises, 273 other. The latest 20:
- Oct 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Oct 2, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 25, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 27, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 6, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 31, 2026EFFECT EDGAR
- Jul 31, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 31, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 30, 2026F-3/A AMENDMENT NO. 1 TO FORM F-3 EDGAR
- Jul 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 25, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 11, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Apr 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
The 306 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 16, 2026 | Ben-Noon AlonChief Executive Officer | Buy | 250,000 | $0.80 | $200.0K | Form 4 |
| Jun 16, 2026 | Eisenberg OrChief Financial Officer | Buy | 250,000 | $0.80 | $200.0K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Rimon Gold Assets LtdSC 13G, 1 filing Dec 9, 202420
- Alon Ben-NoonSC 13G/A, 3 filings Dec 23, 2021 to Feb 13, 202421
- Ariel GordonSC 13G/A, 3 filings Dec 20, 2021 to Feb 13, 202422
- E Europe LtdSC 13G/A, 2 filings Dec 30, 2021 to Mar 15, 202323
- Real Property International LtdSC 13G, 1 filing Mar 15, 202324
Money raised
Private offerings the company reported to the SEC on Form D.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARFerenc Tracik, Chief Medical Officer
- 11SEC EDGARHagit Binder, General Manager
- 12
- 13SEC EDGARCary J. Claiborne, Board member
- 14
- 15SEC EDGARMark Leuchtenberger, Board member
- 16SEC EDGARRoy Golan, Board member
- 17SEC EDGARRevital Mandil-Levin, Board member
- 18
- 19
- 20
- 21
- 22
- 23
- 24